MCID: LYM027
MIFTS: 56

Lymphopenia

Categories: Blood diseases, Immune diseases

Aliases & Classifications for Lymphopenia

MalaCards integrated aliases for Lymphopenia:

Name: Lymphopenia 12 29 54 6 44 15 70
Lymphocytopenia 12 62

Classifications:



External Ids:

Disease Ontology 12 DOID:614
ICD9CM 34 288.51
MeSH 44 D008231
SNOMED-CT 67 48813009
ICD10 32 D72.810
UMLS 70 C0024312

Summaries for Lymphopenia

PubMed Health : 62 About lymphocytopenia: Lymphocytopenia (LIM-fo-si-to-PE-ne-ah) is a disorder in which your blood doesn’t have enough white blood cells called lymphocytes (LIM-fo-sites). These cells are made in the bone marrow along with other kinds of blood cells. Lymphocytes help protect your body from infection. Low numbers of lymphocytes can raise your risk of infection. Lymphocytopenia also is called lymphopenia.

MalaCards based summary : Lymphopenia, also known as lymphocytopenia, is related to alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity and adenosine deaminase deficiency. An important gene associated with Lymphopenia is RAC2 (Rac Family Small GTPase 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Angiotensin II and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and neutrophil, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A leukopenia that is the condition of having an abnormally low level of lymphocytes in the blood.

Wikipedia : 73 Lymphocytopenia is the condition of having an abnormally low level of lymphocytes in the blood.... more...

Related Diseases for Lymphopenia

Diseases related to Lymphopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 675)
# Related Disease Score Top Affiliating Genes
1 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 32.6 RAG1 PTPN22 IL10 FOXP3
2 adenosine deaminase deficiency 31.9 RAG1 JAK3 IL2RG
3 reticular dysgenesis 31.8 RAG1 JAK3 IL2RG
4 neutropenia 30.7 IL2 IL10 G6PC3 FASLG
5 digeorge syndrome 30.6 RAG1 IL7 IL2RG FOXN1 FAS
6 mycosis fungoides 30.2 IL7 IL2RA IL2 FOXP3
7 pancytopenia 30.2 IL2RA G6PC3 FOXP3 CD55
8 graft-versus-host disease 30.2 IL2 IL10 FASLG FAS
9 janus kinase-3 deficiency 30.1 JAK3 IL2RG
10 peripheral t-cell lymphoma 30.0 SELL JAK3 IL2 FOXP3
11 acute graft versus host disease 30.0 IL2RA IL2 IL10 FASLG
12 t-cell adult acute lymphocytic leukemia 29.9 JAK3 IL2RA IL2 FOXP3
13 relapsing-remitting multiple sclerosis 29.9 IL7R IL2 IL10 FOXP3 FAS
14 autoimmune enteropathy 29.9 IL2RA FOXP3
15 t cell deficiency 29.8 SELL RAG1 IL7R IL7 IL2RG IL2
16 adult t-cell leukemia 29.8 JAK3 IL2RA IL2 FOXP3 FAS
17 anca-associated vasculitis 29.8 PTPN22 IL2
18 chronic graft versus host disease 29.8 IL2RA IL10
19 demyelinating disease 29.8 IL7R IL2 IL10 FOXP3
20 idiopathic neutropenia 29.8 IL2RA IL10 FASLG
21 crohn's disease 29.8 PTPN22 IL2RA IL2 IL10 FOXP3
22 type 1 diabetes mellitus 29.7 PTPN22 IL2RA IL2 IL10 FOXP3 FASLG
23 thrombocytopenia 29.7 SELL PTPN22 IL7 IL2 IL10 FOXP3
24 cutaneous t cell lymphoma 29.7 IL7 IL2RA IL2 FAS
25 multiple sclerosis 29.7 PTPN22 IL7R IL7 IL2RA IL2 IL10
26 silicosis 29.7 IL10 FASLG FAS
27 thyroiditis 29.7 PTPN22 IL2 IL10 FOXP3 FASLG
28 dermatitis, atopic 29.7 SELL IL2RA IL2 IL10 FOXP3
29 lymphadenitis 29.7 IL2RA IL10 FASLG FAS
30 sjogren syndrome 29.7 IL2RA IL10 FASLG FAS
31 lymphoma, non-hodgkin, familial 29.7 SELL RAG1 LCK IL7 IL2RA IL2
32 graves' disease 29.6 SELL PTPN22 IL2RA FASLG FAS
33 severe combined immunodeficiency, x-linked 29.6 JAK3 IL7R IL7 IL2RG IL2RA IL2
34 lymphoproliferative syndrome 29.6 IL2RA IL2 IL10 FASLG FAS
35 t-cell lymphoblastic leukemia/lymphoma 29.6 RAG1 LCK IL2RA IL2 FOXP3 FASLG
36 tetanus 29.6 IL7R IL2RA IL2 IL10
37 listeriosis 29.6 SELL IL7R IL10
38 contact dermatitis 29.6 SELL IL7 IL2 IL10
39 severe combined immunodeficiency 29.6 RAG1 RAC2 MYOC MYH7 LCK JAK3
40 cutaneous leishmaniasis 29.6 IL2 IL10 FOXP3
41 autoimmune disease 29.6 PTPN22 LCK JAK3 IL2RA IL2 IL10
42 omenn syndrome 29.5 RAG1 JAK3 IL7R IL7 IL2RG IL10
43 systemic lupus erythematosus 29.4 SELL PTPN22 LCK IL7R IL2RA IL2
44 myelodysplastic syndrome 29.4 IL7 IL2 IL10 FASLG FAS CD55
45 hemolytic anemia 29.4 IL2RA IL2 IL10 FASLG FAS CD55
46 leukemia, chronic lymphocytic 29.4 SELL LCK IL7 IL2RA IL2 IL10
47 chronic mucocutaneous candidiasis 29.4 PTPN22 IL2RA IL2 IL10 FOXP3
48 visceral leishmaniasis 29.4 SELL IL2RA IL2 IL10 FOXP3
49 pulmonary tuberculosis 29.3 IL2RA IL2 IL10
50 autoimmune hepatitis 29.3 IL10 FOXP3 FAS

Graphical network of the top 20 diseases related to Lymphopenia:



Diseases related to Lymphopenia

Symptoms & Phenotypes for Lymphopenia

GenomeRNAi Phenotypes related to Lymphopenia according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-3 10.23 LCK
2 Decreased viability GR00221-A-1 10.23 LCK
3 Decreased viability GR00221-A-2 10.23 LCK
4 Decreased viability GR00221-A-3 10.23 JAK3 LCK
5 Decreased viability GR00249-S 10.23 G6PC3 IL2RA RAC2 SELL
6 Decreased viability GR00301-A 10.23 LCK
7 Decreased viability GR00342-S-1 10.23 LCK
8 Decreased viability GR00342-S-3 10.23 LCK
9 Decreased viability GR00381-A-1 10.23 MYOC
10 Decreased viability GR00386-A-1 10.23 FASLG FOXN1 IL7 LCK RAC2 SELL
11 Decreased viability GR00402-S-2 10.23 FASLG G6PC3 IL2 IL2RA JAK3
12 Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection GR00233-A-1 8.65 LCK
13 Increased the percentage of infected cells GR00402-S-1 8.32 IL10

MGI Mouse Phenotypes related to Lymphopenia:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.43 CD55 FAS FASLG FOXN1 FOXP3 G6PC3
2 endocrine/exocrine gland MP:0005379 10.4 FAS FASLG FOXN1 FOXP3 G6PC3 IL10
3 immune system MP:0005387 10.39 CD55 FAS FASLG FOXN1 FOXP3 G6PC3
4 cardiovascular system MP:0005385 10.35 FAS FASLG FOXN1 FOXP3 IL10 IL2
5 cellular MP:0005384 10.34 FAS FASLG FOXN1 FOXP3 IL10 IL2
6 homeostasis/metabolism MP:0005376 10.33 CD55 FAS FASLG FOXN1 FOXP3 G6PC3
7 mortality/aging MP:0010768 10.27 CD55 FAS FASLG FOXN1 FOXP3 G6PC3
8 digestive/alimentary MP:0005381 10.21 FAS FASLG FOXP3 IL10 IL2 IL2RA
9 liver/biliary system MP:0005370 10.1 FAS FASLG FOXN1 FOXP3 IL10 IL2
10 neoplasm MP:0002006 9.97 FAS FASLG FOXN1 IL10 IL2 IL2RG
11 normal MP:0002873 9.85 FAS FASLG FOXN1 FOXP3 IL10 IL2RG
12 no phenotypic analysis MP:0003012 9.8 FOXP3 IL10 IL2 IL2RG IL7 MYH7
13 respiratory system MP:0005388 9.65 FAS FASLG FOXP3 IL10 IL2 IL2RA
14 vision/eye MP:0005391 9.32 FAS FASLG FOXN1 FOXP3 IL10 IL2

Drugs & Therapeutics for Lymphopenia

PubMed Health treatment related to Lymphopenia: 62

If you have mild lymphocytopenia with no underlying cause, you may not need treatment . The disorder may improve on its own. If you have unusual infections, repeat infections, and/or infections that won't go away due to lymphocytopenia , you'll need treatment for the infections. If you have a disease or condition that's causing lymphocytopenia , your doctor will prescribe treatment for that illness. Treating the underlying problem will help treat the lymphocytopenia.

Drugs for Lymphopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198
2
Gemcitabine Approved Phase 2 95058-81-4 60750
3
Lenograstim Approved, Investigational Phase 2 135968-09-1
4
carbamide peroxide Approved Phase 2 124-43-6
5
Acetaminophen Approved Phase 2 103-90-2 1983
6
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
7
Promethazine Approved, Investigational Phase 2 60-87-7 4927
8
Temozolomide Approved, Investigational Phase 1, Phase 2 85622-93-1 5394
9
Thymalfasin Investigational Phase 2 62304-98-7
10 Imatinib Mesylate Phase 2 220127-57-1 123596
11 Vasodilator Agents Phase 2
12 Angiotensin I (1-7) Phase 2
13 Angiotensinogen Phase 2
14 Antihypertensive Agents Phase 2
15 Anti-Infective Agents Phase 2
16 Anti-Retroviral Agents Phase 2
17 Antiviral Agents Phase 2
18 Anti-HIV Agents Phase 2
19 Plerixafor octahydrochloride Phase 2
20 Pharmaceutical Solutions Phase 2
21 Alkylating Agents Phase 1, Phase 2
22 Adjuvants, Immunologic Phase 2
23 Cholinergic Agents Phase 2
24 Bromides Phase 2
25 Anticonvulsants Phase 2
26 Pyridostigmine Bromide Phase 2 101-26-8
27 Neurotransmitter Agents Phase 2
28 Cholinesterase Inhibitors Phase 2
29
Basiliximab Approved, Investigational Phase 1 179045-86-4, 152923-56-3
30
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
31
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1 1177-87-3
32
belimumab Approved Phase 1 356547-88-1 5957 10451420
33
Fludarabine Approved Phase 1 21679-14-1, 75607-67-9 30751
34
Mesna Approved, Investigational Phase 1 3375-50-6 598
35
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
36
Nelfinavir Approved Phase 1 159989-64-7 64143
37 Mitogens Phase 1
38 Immunoglobulin G Phase 1
39 Interleukin-2 Phase 1
40 Keyhole-limpet hemocyanin Phase 1
41 Freund's Adjuvant Phase 1
42 Antimetabolites Phase 1
43 Immunoglobulins, Intravenous Phase 1
44 Autoantibodies Phase 1
45 Interleukin-4 Phase 1
46 Vaccines Phase 1
47 Immunologic Factors Phase 1
48 Immunosuppressive Agents Phase 1
49 Antirheumatic Agents Phase 1
50 Antiemetics Phase 1

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 A Randomised, Multicentric, Phase 2a Study Evaluating the Impact of an Immunotherapy by IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients Completed NCT01368107 Phase 2 placebo;interleukin 7;interleukin 7;interleukin 7
2 Autologous Cytokine Induced Killer Cells as Adjuvant Adoptive Immunotherapy in Patients With Chronic Myeloid Leukemia on Standard Drug Therapy Completed NCT00815321 Phase 2
3 Ph IIb Study Evaluating the Safety & Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma Completed NCT00771810 Phase 2 TXA127;TXA127;Placebo
4 A Pilot Trial of Thymalfasin (Ta1) to Treat COVID-19 Infection in Patients With Lymphocytopenia Recruiting NCT04487444 Phase 2 Thymalfasin
5 A Phase 2, Open-Label Study to Assess the Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in Patients With Idiopathic CD4 T Cell Lymphocytopenia Recruiting NCT03519464 Phase 2
6 Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models Recruiting NCT02015013 Phase 2 Plerixafor
7 Phase I Study of Autologous Lymphocyte Infusions After Radiation Therapy to Mitigate Radiation Induced Lymphopenia and Enhance Immune Reconstitution in Patients With Solid Tumor Malignancies Recruiting NCT04668833 Phase 2
8 A Phase I/II Dose-escalation Multi Center Study to Evaluate the Safety of Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in coronaviruS pnEumonia and/or Lymphopenia Recruiting NCT04578210 Phase 1, Phase 2
9 A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in France and Belgium Recruiting NCT04407689 Phase 2 Interleukin-7;Placebo
10 A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Infectious Cohort Recruiting NCT04442178 Phase 2 CYT107;Placebo
11 A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Oncology Cohort Recruiting NCT04426201 Phase 2 CYT107;Placebo
12 A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in UK Recruiting NCT04379076 Phase 2 Interleukin-7;Placebos
13 International, Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts (ALC) in Patients With Sepsis Active, not recruiting NCT03821038 Phase 2 Placebos
14 Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma: Comparison of Two Established Schedules Not yet recruiting NCT04019262 Phase 1, Phase 2 Temozolomide Oral Product
15 Study of the Role of Peripheral Acetylcholinesterase Inhibitor Pyridostigmine as Immunomodulators in a Population of Patients Living With Human Immunodeficiency Virus Infection. Suspended NCT03312244 Phase 2 Pyridostigmine Bromide;Placebo
16 Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE) Terminated NCT00839436 Phase 1, Phase 2 CYT107
17 A Phase I Study of CYT107 (Recombinant Glycosylated Human IL-7) in Recipients of HLA Matched Ex Vivo T Cell Depleted Bone Marrow or Peripheral Blood Stem Cell Transplant Completed NCT00684008 Phase 1 CYT107 - Recombinant glycosylated human interleukin 7.;rhIL-7 (CYT107)
18 A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GX-I7 in Healthy Volunteers Completed NCT02860715 Phase 1 GX-I7;Placebo
19 A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers Completed NCT03144934 Phase 1 GX-I7;Placebo
20 Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer Completed NCT00693095 Phase 1
21 REGULATory T-Cell Inhibition With Basiliximab (Simulect®) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme Completed NCT00626483 Phase 1 basiliximab
22 A Pilot Trial of Therapeutic Vaccination With a Modified gp100 Melanoma Peptide (gp100:209-217(210M)), Montanide ISA 51, and KLH With Reconstitution After Chemotherapy to Induce Lymphopenia in Patients With Metastatic Melanoma Completed NCT00091143 Phase 1 fludarabine phosphate
23 A Ph I/IIa Rand Placebo Ctrl, S-Blind Multictr Dose-Esc Study of SC Intermittent Interleukin-7 CYT107 in Chronically HIV-Infected Pts With CD4 T Lymphocyte Counts 101-400 Cells-/mm(3) and Plasma HIV RNA Less Than 50 Copies/mL After at Least 12 M of HAART Completed NCT00477321 Phase 1 CYT 107
24 Phase I Study of Adoptive Transfer of Autologous T Lymphocytes Engrafted With a Chimeric Antigen Receptor Targeting the Kappa Light Chain of Immunoglobulin Expressed in Patients With CLL, B-Cell Lymphoma or Multiple Myeloma Recruiting NCT00881920 Phase 1
25 ADMINISTRATION OF MOST CLOSELY MATCHED THIRD PARTY RAPIDLY GENERATED LMP, BARF1 and EBNA1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES TO PATIENTS WITH EBV-POSITIVE LYMPHOMA AND OTHER EBV-POSITIVE MALIGNANCIES Recruiting NCT02287311 Phase 1 Cyclophosphamide;Fludarabine
26 Phase 1 Therapy With Manufactured Autologous T-Cells Expressing a Second Generation Chimeric Antigen Receptor (CAR) for Treatment of T-Cell Malignancies Expressing CD5 Antigen Recruiting NCT03081910 Phase 1 Fludarabine;Cytoxan
27 A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide Recruiting NCT02659800 Phase 1
28 A Phase I Evaluation of the Safety of Belimumab in People With Idiopathaic CD4 Lymphopenia and Autoantibodies (Phoebe) Recruiting NCT04097561 Phase 1
29 Vaccination to Enhance the Anti-Tumor Activity of GD2 Chimeric Antigen Receptor-Expressing, VZV-Specific T Cells in Subjects With Advanced Sarcomas and Neuroblastoma (VEGAS) Active, not recruiting NCT01953900 Phase 1 Fludarabine;Cyclophosphamide
30 Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme During Recovery From Therapeutic Temozolomide-induced Lymphopenia Active, not recruiting NCT00639639 Phase 1
31 Cell Therapy for High Risk T-Cell Malignancies Using CD7-specific CAR Expressed On Autologous T Cells (CRIMSON) Not yet recruiting NCT03690011 Phase 1 Fludarabine;Cytoxan
32 Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor in the Perioperative Period Terminated NCT00385450 Phase 1 Nelfinavir/placebo
33 EGFRvIII Chimeric Antigen Receptor (CAR) Gene-modified T Cells for Patients With Newly-Diagnosed GBM During Lymphopenia Terminated NCT02664363 Phase 1
34 Evaluation of Immunosuppression in Septic Shock: Biomarkers and Pharmacological Restoration (IMMUNOSEPSIS) Unknown status NCT02803346
35 Regional Differences in Human Immunodeficiency Virus (HIV) Testing Procedures in Eastern German Federal States Unknown status NCT03158987
36 A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma Completed NCT02490930 Early Phase 1 Fingolimod
37 Assessment of Postoperative Lymphopenia as Risk Factor for Postoperative Infections: EVALYMPH Study Completed NCT02799251
38 Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas Completed NCT01653834
39 Study of Prognostic Value of T Cell Receptor Diversity and CD4 Lymphopenia in First Relapse Breast or Lung Cancer Patients Completed NCT01306188
40 Analysis of Clinical and Immunological Characteristics, as Well as Pathophysiological Mechanisms in a French Cohort of Patients With Idiopathic CD4 Lymphocytopenia Completed NCT02113930
41 Evaluation of the Epidemiology, Clinical Manifestations, Etiologies, and Immunology of Human Immunodeficiency Virus (HIV) Negative CD4 T Lymphocyte Deficient Patients Completed NCT00001319
42 Research Into the Molecular Bases of a New Phenotype Combining Premature White Hair, Polycystic Kidney Disease, Aortic Dilation/Dissection and Lymphopenia Completed NCT03651388
43 Lymphocyte Count as a Sign of Immunoparalysis and Its Correlation With Nutritional Status in Septic Pediatric Intensive Care Patients: A Pilot Study Completed NCT02698683
44 Newborn Screening for SCID in a High-Risk Population Completed NCT00845416
45 Identification of Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes: An Analysis of Data From the SAVOR Study Completed NCT01192659
46 Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia Recruiting NCT00867269
47 NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure Recruiting NCT04342104
48 COVID-19 Associated Lymphopenia Pathogenesis Study in Blood Recruiting NCT04401436
49 Study of the Effects of Transcutaneous Vagus Nerve Stimulation on Cancer Patients' Fatigue, Quality of Life and Lymphopenia After Radiotherapy or Chemotherapy Recruiting NCT04563013
50 Study of Lymphopenia as a Specific Biomarker or Prognostic Risk Factor for Disease Severity in Elderly Patients With COVID-19. Not yet recruiting NCT04800731

Search NIH Clinical Center for Lymphopenia

Cochrane evidence based reviews: lymphopenia

Genetic Tests for Lymphopenia

Genetic tests related to Lymphopenia:

# Genetic test Affiliating Genes
1 Lymphopenia 29

Anatomical Context for Lymphopenia

MalaCards organs/tissues related to Lymphopenia:

40
T Cells, Bone Marrow, Neutrophil, Skin, Prostate, Bone, Thymus

Publications for Lymphopenia

Articles related to Lymphopenia:

(show top 50) (show all 8949)
# Title Authors PMID Year
1
Measles virus-induced immunosuppression in SLAM knock-in mice. 54 61
20200244 2010
2
Irradiation and IL-15 promote loss of CD8 T-cell tolerance in response to lymphopenia. 54 61
20075162 2010
3
Development of a quantitative bead capture assay for soluble IL-7 receptor alpha in human plasma. 61 54
19690616 2009
4
False negative results of QuantiFERON TB-2G test in patients with active tuberculosis. 61 54
19628910 2009
5
Injection of glycosylated recombinant simian IL-7 provokes rapid and massive T-cell homing in rhesus macaques. 54 61
19351957 2009
6
Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer. 61 54
19483649 2009
7
Safety and efficacy of treatment using interleukin-2 in a patient with idiopathic CD4(+) lymphopenia and Mycobacterium avium-intracellulare. 61 54
19438596 2009
8
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. 61 54
18971421 2009
9
Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. 54 61
19136960 2009
10
Clinical and immunologic consequences of a somatic reversion in a patient with X-linked severe combined immunodeficiency. 61 54
18728247 2008
11
Priming of T cells to Fas-mediated proliferative signals by interleukin-7. 61 54
18441236 2008
12
IL-7 serum levels and lymphopenia in hemodialysis patients, non-responders to recombinant human erythropoietin therapy. 61 54
18375155 2008
13
Activity of nuclear factor of activated T cells is independent of the number of peripheral lymphocytes in FTY720-treated patients. 54 61
18589120 2008
14
Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery. 54 61
18630487 2008
15
Immunosuppression in islet transplantation. 54 61
18431511 2008
16
A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients. 61 54
18610754 2008
17
Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. 54 61
18205031 2008
18
Immune defects in breast cancer patients after radiotherapy. 54 61
19087768 2008
19
Pharmacology and mechanism of action of forodesine, a T-cell targeted agent. 61 54
18086347 2007
20
[Immunotherapy in radical surgery of colorectal carcinoma]. 54 61
18019635 2007
21
An intense form of homeostatic proliferation of naive CD8+ cells driven by IL-2. 54 61
17664294 2007
22
Apoptosis does not contribute to the blood lymphocytopenia observed after intensive and downhill treadmill running in humans. 61 54
17987505 2007
23
Severe FOXP3+ and naïve T lymphopenia in a non-IPEX form of autoimmune enteropathy combined with an immunodeficiency. 54 61
17484867 2007
24
Relationship between serum IL-7 concentrations and lymphopenia upon different levels of HIV immune control. 54 61
17457102 2007
25
Perspectives on interleukin-7 therapy in HIV infection. 61 54
19372891 2007
26
A three-base-deletion polymorphism in the upstream non-coding region of human interleukin 7 (IL-7) gene could enhance levels of IL-7 expression. 61 54
17373935 2007
27
Idiopathic CD4+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7. 61 54
17053062 2007
28
The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma. 61 54
17198533 2007
29
The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. 61 54
17289551 2007
30
Interleukin 7 receptor alpha-chain-mutation severe combined immunodeficiency without lymphopenia: correction with haploidentical T-cell-depleted bone marrow transplantation. 61 54
17201233 2006
31
Familial NK cell deficiency associated with impaired IL-2- and IL-15-dependent survival of lymphocytes. 61 54
17142786 2006
32
Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. 54 61
16778146 2006
33
Normal interleukin-7 (IL7) levels and normal IL7 response to CD4 T lymphopenia in patients with multiple sclerosis and systemic sclerosis. 61 54
16844418 2006
34
Follow up study on the immune response to low frequency electromagnetic fields in men and women working in a museum. 54 61
17291405 2006
35
Interleukin-7 partially rescues B-lymphopoiesis in osteopetrotic oc/oc mice through the engagement of B220+ CD11b+ progenitors. 54 61
16797412 2006
36
ATM stabilizes DNA double-strand-break complexes during V(D)J recombination. 61 54
16799570 2006
37
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. 61 54
16699374 2006
38
Severe combined immune deficiency in an adenosine deaminase-deficient patient. 54 61
16724639 2006
39
Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. 54 61
16461915 2006
40
Diminished expression of complement regulatory proteins (CD55 and CD59) in lymphocytes from systemic lupus erythematosus patients with lymphopenia. 54 61
17080916 2006
41
Two-tiered universal newborn screening strategy for severe combined immunodeficiency. 54 61
16260163 2005
42
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). 61 54
16131572 2005
43
Role of interleukin-7 in bone and T-cell homeostasis. 61 54
16313348 2005
44
Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy. 61 54
16277025 2005
45
Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. 61 54
16020503 2005
46
Apoptotic markers on lymphocytes and monocytes are unchanged during single hemodialysis sessions using either regenerated cellulose or polysulfone membranes. 61 54
16175944 2005
47
The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. 54 61
15905493 2005
48
Abnormal interleukin-7 function in common variable immunodeficiency. 54 61
15598813 2005
49
Idiopathic CD4+ lymphocytopenia may be due to decreased bone marrow clonogenic capability. 54 61
15746558 2005
50
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. 54 61
15800326 2005

Variations for Lymphopenia

ClinVar genetic disease variations for Lymphopenia:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MYOC NM_000261.2(MYOC):c.1102C>T (p.Gln368Ter) SNV Likely pathogenic 7949 rs74315329 GRCh37: 1:171605478-171605478
GRCh38: 1:171636338-171636338
2 RAC2 NM_002872.5(RAC2):c.184G>A (p.Glu62Lys) SNV Likely pathogenic 464885 rs1555908409 GRCh37: 22:37628882-37628882
GRCh38: 22:37232842-37232842
3 MYH7 NM_000257.4(MYH7):c.2389G>A (p.Ala797Thr) SNV Likely pathogenic 42901 rs3218716 GRCh37: 14:23894525-23894525
GRCh38: 14:23425316-23425316
4 NEK1 NM_001199397.2(NEK1):c.859C>G (p.Pro287Ala) SNV Uncertain significance 598999 rs35222922 GRCh37: 4:170502002-170502002
GRCh38: 4:169580851-169580851
5 JAK3 NM_000215.3(JAK3):c.2452G>A (p.Glu818Lys) SNV Uncertain significance 464099 rs374191135 GRCh37: 19:17943637-17943637
GRCh38: 19:17832828-17832828
6 NEK1 NM_012224.3(NEK1):c.1021G>A (p.Ala341Thr) SNV Uncertain significance 266046 rs189186475 GRCh37: 4:170483347-170483347
GRCh38: 4:169562196-169562196

Expression for Lymphopenia

Search GEO for disease gene expression data for Lymphopenia.

Pathways for Lymphopenia

Pathways related to Lymphopenia according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 SELL RAG1 PTPN22 LCK JAK3 IL7R
2
Show member pathways
13.84 RAC2 MYH7 JAK3 IL7R IL7 IL2RG
3
Show member pathways
13.68 JAK3 IL7R IL7 IL2RG IL2RA IL2
4
Show member pathways
13.54 RAC2 JAK3 IL7R IL7 IL2RG IL2RA
5
Show member pathways
13.43 RAC2 LCK JAK3 IL7R IL7 IL2RG
6
Show member pathways
13.4 RAG1 LCK JAK3 IL7R IL7 IL2RG
7
Show member pathways
13.32 SELL RAC2 LCK JAK3 IL2RG IL2RA
8
Show member pathways
13.28 RAC2 PTPN22 MYH7 IL7R IL7 IL2RG
9
Show member pathways
13.03 JAK3 IL7R IL7 IL2RG IL2RA IL2
10
Show member pathways
12.86 JAK3 IL2RG IL2RA IL2 FASLG FAS
11
Show member pathways
12.81 JAK3 IL7R IL7 IL2RG IL2RA IL2
12 12.81 RAC2 JAK3 IL7R IL7 IL2RG IL2RA
13
Show member pathways
12.8 RAC2 MYH7 IL2RA IL2 IL10 FOXP3
14
Show member pathways
12.78 LCK JAK3 IL2RG IL2RA IL2
15
Show member pathways
12.66 LCK JAK3 IL2RG IL2RA IL2 IL10
16
Show member pathways
12.55 RAC2 LCK IL2 FASLG FAS
17
Show member pathways
12.47 JAK3 IL7R IL7 IL2RG IL2RA IL2
18
Show member pathways
12.43 RAC2 LCK IL2RG IL2RA IL2
19 12.38 LCK JAK3 IL2RG IL2RA IL2
20
Show member pathways
12.33 IL2RG IL2RA IL2 IL10
21
Show member pathways
12.22 RAC2 LCK JAK3 IL2RG IL2RA IL2
22 12.17 RAG1 PTPN22 LCK JAK3 IL2RA IL2
23
Show member pathways
12.15 RAG1 IL7R IL10 G6PC3 FASLG
24
Show member pathways
12.14 LCK JAK3 IL2RG IL2RA IL2
25 12.12 RAC2 LCK IL2 IL10
26
Show member pathways
12.06 LCK IL2RG IL2RA IL2 FASLG
27 12.05 SELL IL7R IL7 IL2RA IL2 IL10
28 12.02 JAK3 IL2RG IL10 FASLG
29 11.95 IL7R IL7 IL2RA CD55
30 11.87 IL7R IL7 IL2RA IL2 IL10
31
Show member pathways
11.85 JAK3 IL2RG FOXP3
32
Show member pathways
11.82 IL2RA IL2 FOXP3 FASLG
33 11.8 SELL IL7R IL2 IL10
34
Show member pathways
11.71 IL2RG IL2RA IL2 FASLG
35 11.69 IL2RA IL10 FOXP3
36 11.67 JAK3 IL2RG IL10
37 11.66 JAK3 IL7R IL7 IL2RG IL2RA IL2
38 11.57 IL2 FASLG FAS
39
Show member pathways
11.54 JAK3 IL7R IL7 IL2RG IL2RA
40 11.53 LCK IL7R IL2RA
41
Show member pathways
11.53 LCK JAK3 IL2RG IL2RA IL2 FOXP3
42 11.43 RAG1 LCK JAK3 IL7R IL2RG
43 11.42 IL10 FASLG FAS
44 11.42 LCK IL2RG IL2RA IL2
45 11.4 JAK3 IL2RG IL2RA IL2 IL10 FOXP3
46 11.3 IL7 IL2 IL10
47
Show member pathways
11.3 LCK JAK3 IL2RG IL2RA IL2
48 11.21 RAG1 JAK3 IL7R IL7 IL2RG
49 11.01 RAC2 IL7 IL2 IL10 FASLG
50
Show member pathways
10.72 IL2RG IL2RA IL2 IL10 FOXP3 FASLG

GO Terms for Lymphopenia

Cellular components related to Lymphopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.26 LCK FASLG FAS CD55
2 external side of plasma membrane GO:0009897 9.02 IL7R IL2RG IL2RA FASLG FAS

Biological processes related to Lymphopenia according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.05 RAC2 IL7R IL7 IL2 FASLG
2 MAPK cascade GO:0000165 9.97 JAK3 IL2RG IL2RA IL2
3 cytokine-mediated signaling pathway GO:0019221 9.87 JAK3 IL7 IL2RG IL2RA IL2 IL10
4 response to lipopolysaccharide GO:0032496 9.85 PTPN22 IL10 FOXP3 FASLG
5 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.83 LCK FASLG FAS
6 B cell differentiation GO:0030183 9.82 RAG1 JAK3 IL10
7 negative regulation of tumor necrosis factor production GO:0032720 9.81 PTPN22 IL10 FOXP3
8 negative regulation of interleukin-6 production GO:0032715 9.81 PTPN22 IL10 FOXP3
9 negative regulation of inflammatory response GO:0050728 9.81 IL2RA IL2 IL10 FOXP3
10 hemopoiesis GO:0030097 9.79 LCK IL10 FOXN1
11 positive regulation of T cell proliferation GO:0042102 9.76 JAK3 IL2RA IL2
12 T cell differentiation GO:0030217 9.73 PTPN22 LCK IL7R IL2
13 negative regulation of T cell proliferation GO:0042130 9.71 IL2RA IL10 FOXP3
14 interleukin-7-mediated signaling pathway GO:0038111 9.67 JAK3 IL7R IL7 IL2RG
15 negative regulation of immune response GO:0050777 9.66 IL2RA FOXP3
16 positive regulation of regulatory T cell differentiation GO:0045591 9.65 IL2 FOXP3
17 interleukin-15-mediated signaling pathway GO:0035723 9.65 JAK3 IL2RG
18 negative regulation of T-helper 17 cell differentiation GO:2000320 9.63 IL2 FOXP3
19 regulation of regulatory T cell differentiation GO:0045589 9.63 IL2RA IL2 FOXP3
20 negative regulation of T cell apoptotic process GO:0070233 9.62 RAG1 IL7R
21 interleukin-9-mediated signaling pathway GO:0038113 9.62 JAK3 IL2RG
22 necroptotic signaling pathway GO:0097527 9.61 FASLG FAS
23 immune response GO:0006955 9.61 RAG1 IL7R IL7 IL2RG IL2RA IL2
24 negative regulation of thymocyte apoptotic process GO:0070244 9.6 RAG1 JAK3
25 interleukin-21-mediated signaling pathway GO:0038114 9.59 JAK3 IL2RG
26 regulation of complement-dependent cytotoxicity GO:1903659 9.58 IL10 CD55
27 negative regulation of lymphocyte proliferation GO:0050672 9.58 IL2RA IL2 FOXP3
28 activation-induced cell death of T cells GO:0006924 9.57 IL2RA FAS
29 T cell lineage commitment GO:0002360 9.56 IL7 FOXN1
30 positive regulation of T cell differentiation GO:0045582 9.56 RAG1 IL7 IL2RA IL2
31 interleukin-4-mediated signaling pathway GO:0035771 9.52 JAK3 IL2RG
32 positive regulation of plasma cell differentiation GO:1900100 9.49 IL2 IL10
33 regulation of T cell homeostatic proliferation GO:0046013 9.48 IL2RA IL2
34 interleukin-2-mediated signaling pathway GO:0038110 9.46 JAK3 IL2RG IL2RA IL2
35 T cell homeostasis GO:0043029 9.02 RAG1 JAK3 IL2RA FOXP3 FOXN1

Molecular functions related to Lymphopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.35 SELL RAG1 RAC2 PTPN22 MYOC MYH7
2 cytokine activity GO:0005125 9.62 IL7 IL2 IL10 FASLG
3 glycosphingolipid binding GO:0043208 9.26 SELL IL2
4 interleukin-2 binding GO:0019976 9.16 IL2RG IL2RA
5 interleukin-2 receptor activity GO:0004911 8.96 IL2RG IL2RA
6 interleukin-7 receptor activity GO:0004917 8.62 IL7R IL2RG

Sources for Lymphopenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....